• Profile
Close

Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: The ABIDE project

JAMA Oct 10, 2018

de Wilde A, et al. - In an unselected memory clinic cohort, researchers investigated the correlation of amyloid positron emission tomography (PET) with changes in diagnosis, diagnostic confidence, treatment, and patients’ experiences. This prospective diagnostic study allows a bridge between validating amyloid PET in a research setting and applying this diagnostic tool to daily clinical practice. Findings revealed considerable associations of both amyloid-positive and amyloid-negative results with changes in diagnosis and treatment, both in patients with and without dementia.

Methods

  • Between January 2015 and December 2016, 866 patients who visited the tertiary memory clinic at the VU University Medical Center were offered amyloid PET using fluoride-18 florbetaben as part of a routine diagnostic dementia workup.
  • Of these, researchers included 476 (55%) and excluded 32 (4%); 358 (41%) patients did not participate.
  • To supplement this sample, they included 31 patients with mild cognitive impairment from the University Medical Center Utrecht memory clinic.
  • Neurologists assessed a preamyloid and postamyloid PET diagnosis for each patient that consisted of both a clinical syndrome (dementia, mild cognitive impairment, or subjective cognitive decline) and a suspected etiology (Alzheimer disease [AD] or non-AD), with a confidence level ranging from 0% to 100%.
  • In addition, patient treatment, in terms of ancillary investigations, medication, and care, was determined by the neurologist.
  • One year after being scanned, they followed-up each patient.
  • Post-PET changes in diagnosis, diagnostic confidence, and patient treatment were assessed as primary outcome measure.

Results

  • Among the 507 patients (mean [SD] age, 65 (8) years; 201 women [39%]; mean [SD] Mini-Mental State Examination score, 25 [4]), 164 (32%) displayed AD dementia, 70 (14%) non-AD dementia, 114 (23%) mild cognitive impairment, and 159 (31%) subjective cognitive decline.
  • For 242 patients (48%), positive amyloid PET results were observed.
  • After undergoing amyloid PET, change in the suspected etiology was noted for 125 patients (25%), more often due to a negative (82 of 265 [31%]) vs a positive (43 of 242 [18%]) PET result (P < .01).
  • Older patients (>65 years) displayed post-PET changes in suspected etiology more frequently than those younger (<65 years) than the typical age of onset at 65 years (74 of 257 [29%] vs 51 of 250 [20%]; P < .05).
  • Increase in mean diagnostic confidence (SD) from 80 (13) to 89 (13%) was noted (P < .001).
  • A change in patient treatment post-PET was noted in 123 patients (24%), mostly related to additional investigations and therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay